Skip to main content
. 2023 Jan 11;15(2):459. doi: 10.3390/cancers15020459

Figure 4.

Figure 4

CircZBTB46 protects AML cells against ferroptosis. (A) Relative cell death of HL-60 cells under control conditions (si-NC) or upon circZBTB46 knockdown (si-circZBTB46). (B) Relative cell death of control and circZBTB46-knockdown cells following treatment with RSL3 or RSL3 + ferrostatin-1. (C) Relative lipid ROS levels of HL-60 cells under control conditions (si-NC) or upon circZBTB46 knockdown (si-circZBTB46). ROS, reactive oxygen species. (D) Relative lipid ROS levels of control and circZBTB46-knockdown cells following treatment with RSL3 or RSL3 + ferrostatin-1. (E) Relative MDA levels of HL-60 cells under control conditions (si-NC) or upon circZBTB46 knockdown (si-circZBTB46). MAD, malondialdehyde. (F) Relative MDA levels of control and circZBTB46-knockdown cells following treatment with RSL3 or RSL3 + ferrostatin-1. (G) Relative cell death of control and circZBTB46-overexpression cells following treatment with RSL3 or RSL3 + ferrostatin-1. (H) Relative lipid ROS levels of control and circZBTB46-overexpression cells following treatment with RSL3 or RSL3 + ferrostatin-1. (I) Relative MDA levels of control and circZBTB46-overexpression cells following treatment with RSL3 or RSL3 + ferrostatin-1. Data were presented as mean ± SD. The two-tailed p values were determined with either an unpaired Student’s t test (B,D,F–I) or a one-way ANOVA (A,C,E); * p < 0.05, ** p < 0.01. See also Figure S4.